• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Rapid Progress in Bench-to-Clinic Reported for Several Cancers

Article

The results were presented at the recent Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, a meeting jointly sponsored by the NCI, AACR, and EORTC.

A second investigational drug in the isocitrate dehydrogenase (IDH) inhibitor class has demonstrated activity in acute myeloid leukemia (AML), a small clinical study showed.

Seven of 14 patients with relapsed or refractory AML had objective responses to treatment with AG-120, an orally available inhibitor of IDH1. The clinical activity included four complete responses.

The drug has been well tolerated during the ongoing phase I trial to identify the optimal dose for continued clinical evaluation, Daniel Pollyea, MD, assistant professor of medicine at the University of Colorado in Denver, reported at the Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.

Earlier this year, another small phase I study showed activity with the IDH2 inhibitor AG-221, which resulted in objective responses in six of seven patients with relapsed or refractory AML.

Link to the report on Medpage Today: http://bit.ly/1I9dX4R

Related Videos
Will Shapiro
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.